Prolonged exposure therapy

ANANDA Scientific Announces First Patient Enrolled in FDA-approved Clinical Trial Evaluating a Potential New Treatment for Social Anxiety Disorder (SAD)

Retrieved on: 
Tuesday, March 28, 2023
Research, Mental Health, FDA, Cannabis, Clinical Trials, Biotechnology, Pharmaceutical, Health, Natural Resources, Science, National Center for Complementary and Integrative Health, Alternative medicine, NCCIH, NYU, Clinical trial, Neuroimaging, New York University Grossman School of Medicine, SAD, Multimedia, Doctor of Philosophy, Prolonged exposure therapy, Assistant, TSST, Trier social stress test, Master of Science, Psychiatry, Social anxiety disorder, IND, NIH, Cannabidiol, Pharmaceutical industry, Anxiety, MD, CBD

ANANDA Scientific Inc. , a research focused bio-pharmaceutical company today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder (SAD).

Key Points: 
  • ANANDA Scientific Inc. , a research focused bio-pharmaceutical company today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder (SAD).
  • The National Center for Complimentary and Integrative Health (NCCIH-a division of the NIH) is providing funding for this trial which is being conducted at the NYU Grossman School of Medicine .
  • ( Clinical Trials.gov Identifier: NCT05571592 )
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230328005224/en/
    Pictured above are Principal Investigators Naomi Simon MD, MSc, Esther Blessing MD, PhD, and Ananda Scientific CEO Sohail Zaidi.

Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, AIS, Brain, Vasodilation, Trial of the century, Tissue, Safety, Patient, Oxygen, PEGylation, Clinical trial, ISC, Ambient occlusion, Interventional Neuroradiology, Collateral circulation, Plasma, Baptist Health, Principal, Medication, Pharmaceutical industry, Prolonged exposure therapy

Prolong Pharmaceuticals, a clinical stage biopharmaceutical company, today announced that preliminary data from the recently completed Phase 1 clinical study of PP-007 (HEMERA-1) in acute ischemic stroke (AIS) patients will be presented in the Late-Breaking Science session during ISC 2023 in Dallas, TX and in the forthcoming PAIRS conference in Dubai.

Key Points: 
  • Prolong Pharmaceuticals, a clinical stage biopharmaceutical company, today announced that preliminary data from the recently completed Phase 1 clinical study of PP-007 (HEMERA-1) in acute ischemic stroke (AIS) patients will be presented in the Late-Breaking Science session during ISC 2023 in Dallas, TX and in the forthcoming PAIRS conference in Dubai.
  • PP-007 (PEGylated carboxyhemoglobin, bovine) is a novel investigational biopharmaceutical product that improves microvascular perfusion while promoting transfer of oxygen to oxygen-deprived (hypoxic) cells and tissues.
  • HEMERA-1 is the first clinical trial of PP-007 in AIS.
  • PP-007’s multi-modal mechanism of action includes (1) increased blood flow and vasodilation of collateral circulation, (2) targeted delivery of oxygen in ischemic areas for 24 hours, and (3) plasma expansion.

PESI gifts $1.25 million to UC College of Medicine

Retrieved on: 
Thursday, February 9, 2023
Science, Veteran, Eye movement desensitization and reprocessing, Cognitive processing therapy, Eye movement, PTSD, DSM-IV codes, Chard, Prolonged exposure therapy, Research, CPT, Knowledge, UC, Trauma, EMDR, PESI, Doctor of Philosophy, Psychiatry, Nursing, Meat

EAU CLAIRE, Wis., Feb. 9, 2023 /PRNewswire/ -- A $1.25 million gift from PESI will allow researchers at the UC College of Medicine to explore therapies used for posttraumatic stress disorder (PTSD).

Key Points: 
  • "I'm incredibly grateful to PESI for allowing me to make an important and valuable contribution to the science," Chard said.
  • "People are looking for answers and want to trust that the therapy they are offered will work.
  • This study offers a significant step forward in helping us understand how many viable treatment options there are for people suffering from stress responses."
  • "Our mission is to connect knowledge with the needs of mental health clinicians," said Mike Conner, executive director of PESI.

ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)

Retrieved on: 
Wednesday, November 30, 2022
Research, FDA, Cannabis, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Natural Resources, Trier social stress test, Cannabidiol, US Food Sovereignty Alliance, Principal investigator, Doctor of Philosophy, Alternative medicine, Food, Multimedia, IND, New York University Grossman School of Medicine, Master of Science, National Center for Health Research, Prolonged exposure therapy, Cannabinoid, NYU, Neuroimaging, TSST, UCLA, Psychiatry, Assistant, NIH, Social anxiety disorder, Research, PTSD, LDS, Clinical trial, FDA, Pharmaceutical industry, Medical device, Anxiety, MD, CBD

ANANDA Scientific Inc ., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDAs proprietary Liquid Structure delivery technology as a potential treatment for Social Anxiety Disorder.

Key Points: 
  • ANANDA Scientific Inc ., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDAs proprietary Liquid Structure delivery technology as a potential treatment for Social Anxiety Disorder.
  • ( Clinical Trials.gov Identifier: NCT05571592 )
    This press release features multimedia.
  • We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition, said Dr Simon.
  • ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD , Radiculopathic Pain , Anxiety and Opioid Use Disorder ( Mt.

Announcing New Leadership for Alsana® Eating Disorder Treatment Programs in St. Louis, MO

Retrieved on: 
Monday, March 28, 2022
Eating, Housing, CBT, Hounslow and Richmond Community Healthcare NHS Trust, Mental health, Extension, Parent, Topical steroid withdrawal, Lists of diseases, DBT, IOP, Prolonged exposure therapy, Dialectical behavior therapy, Social justice, Cognitive behavioral therapy, SR, University of Missouri School of Medicine, Missouri School of Journalism, Time, PHP, LCSW, Eating disorder, MSW, University, ECHO, Management, Medicine, Dentistry, St. Louis

WESTLAKE VILLAGE, Calif., March 28, 2022 /PRNewswire/ -- Rebekah Freese, MSW, LCSW, Ph.D., has joined Alsana, an eating recovery community and treatment provider, as Sr. Regional Executive Director. She leads Alsana's multidisciplinary eating disorder treatment teams for Residential and PHP/IOP programs in Pacific, Ballwin, and Fenton, Missouri.

Key Points: 
  • WESTLAKE VILLAGE, Calif., March 28, 2022 /PRNewswire/ -- Rebekah Freese, MSW, LCSW, Ph.D., has joined Alsana , an eating recovery community and treatment provider, as Sr.
  • She leads Alsana's multidisciplinary eating disorder treatment teams for Residential and PHP/IOP programs in Pacific , Ballwin , and Fenton , Missouri.
  • Freese joins the team during a time when expanding access to eating disorder care has never been more crucial.
  • "It connects an interdisciplinary team of eating disorder experts with other providers in the community to advanced skills and best practices."